Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$OTLC Ask just got cleared.. .17 break looming I believe..
$OTLC my #1 Covid play..and it’s not even close..watching the strong loading volume here again today..feels like .17 break is looming..
huge potential for OTLC, with omicron raging around the world 2022 can be huge for them
$OTLC Strong volume here..as this looks to be setting up for a .17 break..
It'll come. Just biding its time here and doing some churning in a nice healthy area but this will pop soon. Conference coming up the 25th through 27th and they're going to be presenting on their mesothelioma treatment so I'm expecting big things leading up into that a little later in the month.
Why 2022 Could Open Gangbusters for Covid Stocks (AZN, OTLC, NVAX, PFE, MRNA, MRK, JNJ, BNTX)
Oncotelic Therapeutics Inc (OTC:OTLC) bills itself as an artificial intelligence driven immuno-oncology company with a robust pipeline of first in class TGF-ß immunotherapies for late stage cancers such as gliomas, pancreatic cancer and melanoma. The Covid-19 story here is also compelling.
OT-101, the lead immuno-oncology drug candidate of Oncotelic, is a first-in-class anti-TGF-ß RNA therapeutic that exhibited single agent activity in relapsed/refractory cancer patients. OT-101 also has shown activity against SARS-CoV-2 and has completed a phase 2 trial against COVID-19, with data cleaning and evaluation and datalock ongoing.
Oncotelic Therapeutics Inc (OTC:OTLC) most recently announced that it has performed mutational analysis of SARS-CoV-2 and demonstrated that the open reading frames 8 (ORF8) is potentially driving the evolution of the Delta and the Omicron variants. ORF8 protein is abundantly secreted in COVID patients.
Fatality in hospital patients is associated with higher serum levels of ORF8. ORF8 is one of the least well conserved and most variable parts of the SARS-CoV-2 genome.
“It is gratifying to identify what we think is the fundamental evolutionary pathway for SARS-CoV-2,” said Dr. Vuong Trieu, CEO and Chairman of Oncotelic. “The analysis allows us to position our therapeutic and vaccine platform against ORF8 to address this pandemic as it further mutates.”
OTLC shares are up over 60% in the past six weeks, leading the Covid stock space. The stock is also cheap, trading at just $0.16/share, but with upward trending technical dynamics, including its recent breakout above its 50-day moving average.
Oncotelic Therapeutics Inc (OTC:OTLC) noted in its release that it has identified 30 high entropy amino acid residues which underwent a progressive evolution to arrive at the current dominant variant – Delta variant. The virus underwent mutational waves, with the first wave made up of structural proteins important in its infectivity, and the second wave made up of the ORFs important for its contagion. The most important driver of the second wave is ORF8 mutations at residue 119 and 120. Further mutations of these two residues are creating new lineage trees that are offshoots from the Delta backbone. More importantly the further mutational expansion of the S-protein in the emerging Omicron variant is now followed with the acquisition of ORF8 mutations 119 and 120.
Novavax Inc. (NASDAQ:NVAX) focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome.
The stock has become a johnny-come-lately potential star for speculators in principle if not in fact as the allure of its more simple, easier to store, easier to manufacture, easier to transport, more traditional yet still effective vaccine solution has been widely touted as a potential long-term winner because it translates better to emerging markets around the world, where new variants are thought to be incubating.
https://www.benzinga.com/pressreleases/22/01/ab24866863/why-2022-could-open-gangbusters-for-covid-stocks-azn-otlc-nvax-pfe-mrna-mrk-jnj-bntx
Looking to crack those pesky .17s once and for all..
definitely huge upside once we break this pesky .17 area
Great article. I like this part.
"OTLC shares are up over 60% in the past six weeks, leading the Covid stock space. The stock is also cheap, trading at just $0.16/share, but with upward trending technical dynamics, including its recent breakout above its 50-day moving average."
$OTLC mentioned with some other big names as covid stocks to watch for 2022!
https://www.benzinga.com/pressreleases/22/01/ab24866863/why-2022-could-open-gangbusters-for-covid-stocks-azn-otlc-nvax-pfe-mrna-mrk-jnj-bntx
Covid play remains under the radar..thinking that will change as they continue to make progress
looks like $OTLC is making serious strides with their Covid research
https://www.otcmarkets.com/stock/OTLC/news/ONCOTELIC-ANNOUNCES-THAT-ORF8-MUTATIONS-ARE-DRIVING-THE-EVOLUTION-OF-THE-DELTA-AND-THE-OMICRON-VARIANTS?id=336776
.17 ripe to fall here..looks tin for a .20 test
big conference presentation Jan 25-27 for OTLC, there is usually big news released ahead of these types of things - something to keep an eye on
https://www.otcmarkets.com/stock/OTLC/news/Oncotelics-Dr-Anthony-Maida-to-Present-at-2nd-Annual-TGF--for-Immuno-Oncology-Drug-Development-Summit-in-January-2022?id=335678
$OTLC ONCOTELIC ANNOUNCES THAT ORF8 MUTATIONS ARE DRIVING THE EVOLUTION OF THE DELTA AND THE OMICRON VARIANTS.
AGOURA HILLS, Calif., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC), a leading developer of TGF-ß therapeutics for oncology and virology, today announced that it has performed mutational analysis of SARS-CoV-2 and demonstrated that the open reading frames 8 (“ORF8”) is potentially driving the evolution of the Delta and the Omicron variants. ORF8 protein is abundantly secreted in COVID patients. Fatality in hospital patients is associated with higher serum levels of ORF8. ORF8 is one of the least well conserved and most variable parts of the SARS-CoV-2 genome.
“It is gratifying to identify what we think is the fundamental evolutionary pathway for SARS-CoV-2,” said Dr. Vuong Trieu, CEO and Chairman of Oncotelic. “The analysis allows us to position our therapeutic and vaccine platform against ORF8 to address this pandemic as it further mutates.”
Mutational analysis of SARS-CoV-2. ORF8 and the evolution of the Delta and Omicron variants. Gopika Trieu, Vuong N Trieu. medRxiv 2021.12.19.21268069; doi: https://doi.org/10.1101/2021.12.19.21268069. https://www.medrxiv.org/content/10.1101/2021.12.19.21268069v1
In our analysis, we identified 30 high entropy amino acid residues which underwent a progressive evolution to arrive at the current dominant variant - Delta variant. The virus underwent mutational waves, with the first wave made up of structural proteins important in its infectivity, and the second wave made up of the ORFs important for its contagion. The most important driver of the second wave is ORF8 mutations at residue 119 and 120. Further mutations of these two residues are creating new lineage trees that are offshoots from the Delta backbone. More importantly the further mutational expansion of the S-protein in the emerging Omicron variant is now followed with the acquisition of ORF8 mutations 119 and 120.
The Delta variant evolved to surpass the endogenous resistant to the virus in India and it is likely that the next evolutionary offshoot from the Omicron will evolve to surpass the endogenous resistant to the virus in Africa. Further mutational changes to ORF8 could create a stronger variant of the Delta lineage or grafting of the F120 mutation onto other backbones, such as the Omicron backbone, and which could also potentially create a stronger variant. It is imperative that we leverage our current breathing room to engineer therapeutics such as Artemisinin and OT-101 on top of vaccine targeting ORF8 for a long-drawn-out war against this virus.
Supporting publications are as below:
[1] F.M. Uckun et al., Repurposing Anti-Malaria Phytomedicine Artemisinin as a COVID-19 Drug, Front. Pharmacol. 12 (2021) 407. https://doi.org/10.3389/FPHAR.2021.649532/BIBTEX.
[2] F.M. Uckun, V. Trieu, Targeting Transforming Growth Factor-beta for Treatment of COVID-19-associated Kawasaki Disease in Children, 3 (2020) 19–21. https://doi.org/10.1542/hpeds.2020-0123.Harahsheh.
[3] F.M. Uckun, L. Hwang, V. Trieu, Selectively targeting TGF-ß with Trabedersen/OT-101 in treatment of evolving and mild ards inCOVID-19, Clin. Investig. (Lond). 10 (2020) 35–44. https://doi.org/10.37532/2041-6792.2020.10(2).166.
[4] V. Trieu et al., Targeting TGF-ß pathway with COVID-19 Drug Candidate ARTIVeda/PulmoHeal Accelerates Recovery from Mild-Moderate COVID-19, MedRxiv. (2021) 2021.01.24.21250418. https://doi.org/10.1101/2021.01.24.21250418.
About Oncotelic Therapeutics
Oncotelic Therapeutics, Inc. (f/k/a Mateon Therapeutics, Inc.) ("Oncotelic"), was formed in the State of New York in 1988 as OXiGENE, Inc., was reincorporated in the State of Delaware in 1992, and changed its name to Mateon Therapeutics, Inc. in 2016, and Oncotelic Therapeutics, Inc. in November 2020.
Oncotelic is an artificial intelligence driven immuno-oncology company with a robust pipeline of first in class TGF-ß immunotherapies for late stage cancers such as gliomas, pancreatic cancer and melanoma. OT-101, the lead immuno-oncology drug candidate of Oncotelic, is a first-in-class anti-TGF-ß RNA therapeutic that exhibited single agent activity in relapsed/refractory cancer patients. OT-101 also has shown activity against SARS-CoV-2 and has completed a phase 2 trial against COVID-19 with data cleaning and datalock ongoing. Oncotelic is seeking to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on rare pediatric cancers. Oncotelic also has rare pediatric designation for DIPG (OT-101), melanoma (CA4P), and AML (OXi 4503). The Company also acquired PointR Data Inc. ("PointR") in November 2019.
For more information, please visit www.oncotelic.com
Oncotelic's Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, prospects, plans and objectives of management are forward-looking statements. Words such as "may", "expect", "anticipate" "hope", "vision", "optimism", "design", "exciting", "promising", "will", "conviction", "estimate," "intend," "believe", "quest for a cure of cancer", "innovation-driven", "paradigm-shift", "high scientific merit", "impact potential" and similar expressions are intended to identify forward-looking statements. Forward looking statements contained in this press release include, but are not limited to, statements about future plans, the progress, timing, clinical development, scope and success of future clinical trials, the reporting of clinical data for the company's product candidates and the potential use of the company's product candidates to treat various cancer indications. Each of these forward-looking statements involves risks and uncertainties, and actual results may differ materially from these forward-looking statements. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, failure of collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes. These risks are not exhaustive, the company faces known and unknown risks, including the risk factors described in the Company's annual report on Form 10-K filed with the SEC on April 15, 2021 and in the company's other periodic filings. Forward-looking statements are based on expectations and assumptions as of the date of this press release. Except as required by law, the company does not assume any obligation to update forward-looking statements contained herein to reflect any change in expectations, whether as a result of new information future events, or otherwise.
Contact Information:
For Oncotelic Therapeutics, Inc.:
Amit Shah
ashah@oncotelic.com
https://www.otcmarkets.com/stock/OTLC/news/ONCOTELIC-ANNOUNCES-THAT-ORF8-MUTATIONS-ARE-DRIVING-THE-EVOLUTION-OF-THE-DELTA-AND-THE-OMICRON-VARIANTS?id=336776
$OTLC Breakout time..
$OTLC .17 test here…
This has seen some strong consolidation the past week or so and I think it's about to break out of that zone in a big way.
$OTLC currently consolidating between the 50 and 200 DMA - looking for break to the upside this week https://schrts.co/fptPvwSJ
hoping with the slow holiday week over we can get to work on knocking out that .17 resistance
$OTLC a QB stock that looked to be gearing up last week for a .20 test..one of my top Covid plays with a ton of potential.. check out the website for great DD..
http://www.oncotelic.com/
Looking forward to kicking off the new year here..lots to like about this Covid play..
That's supposed to say green here not green hair in my previous post. Lol.
Nice and green hair. I like the strong volume we have today. Looks good for next week if the volume keeps up and we stay Green in my opinion.
Getting oh so close here..
Looks close to breaking .17 now, up on the ask
$OTLC big bids moving higher..could be gearing up for .20 test here..
Agreed..once again..strong volume here..
Beautiful. That .17 was a good resistance zone to break. Showing very minor resistance at .18 but I think we get over that pretty quick. Looks real good here.
.17 just cleared! Here comes .20!
Good morning OTLC board. Looking forward to a good close to the week and the year.
Agreed, would love to close the year out with a bang above .17
Let’s see if .17 falls today..been getting real close..
$OTLC Strong buys just took this green..love the accumulation here..
$OTLC nice green open here..love the bids in place..
Two trading days left of the year so it'll be curious to see what happens today and tomorrow but I think we'll see continued bargain hunting and people scooping up cheap shares so volume should be good. Just my opinion.
$OTLC forming a bull flag pennant on the daily chart, watch for .17 break for next leg up. https://schrts.co/qtIyfspB
Looks like your not alone..some nice volume here..shares look to be accumulating for that .17 break..
Agreed. Not a lot going to go on for the next couple of days so I've just been bargain hunting all week.
Agreed..and some strong loading looks to be taken place…17 sends it I believe..
This is the week to load IMO, too many potential catalysts upcoming to not score a win here
$OTLC Strong loading continues..fast becoming my favorite Covid stock..
Feels like it’s coming..nice early volume here..
Followers
|
14
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
956
|
Created
|
08/23/16
|
Type
|
Free
|
Moderators |
Oncotelic is actively seeking collaborations with corporations, academic institutions, and patient groups to advance our programs.
We have a history of successful partnerships and welcome new collaboration and licensing opportunities.
Interested parties may contact:
Chulho Park PhD, Chief Technology Officer
Oncotelic Inc.
29397 Agoura Rd., Suite 107
Agoura Hills, CA 91301
bd@oncotelic.com
(650) 635-7000
Through our history of collaborative research, Mateon has supported clinical research projects in the United Kingdom (UK) led by
Cancer Research UK (CRUK) along with additional academic partners.
Currently, we are supporting the PAZOFOS study (NCT02055690), which is being led by The Christie Hospital NHS Foundation Trust
and coordinated by the Manchester Academic Health Science Centre,
Trials Coordination Unit, or MAHSC-CTU, with additional support from The University of Manchester, the Royal Marsden NHS Foundation Trust,
and Mount Vernon Cancer Centre (part of the East and North Hertfordshire NHS Trust).
This Phase 1b/2 study is evaluating the combination of CA4P (fosbretabulin) with the tyrosine kinase inhibitor pazopanib (Votrient®) versus pazopanib
alone for the treatment of advanced recurrent ovarian cancer.
We are providing CA4P for use in this trial.
Continuing in our history of collaborative research, Mateon is providing investigational drug to the Markey Cancer Center for their study Study MCC-2016-08 (NCT03014297).
The study is designed as a single center, open label, phase 1 clinical trial for patients with grade 1-3 gastroenteropancreatic neuroendocrine tumors.
In the first part of the study, up to 15 patients will be treated with everolimus in combination with two different dosing regimens of
CA4P to establish appropriate CA4P dosing levels and evaluate the safety of the drug combination.
The second part of the study is designed to enroll 15 additional patients for assessment of additional safety and efficacy data.
Patients enrolled in MCC-2016-088 will be treated with CA4P and everolimus for 12 weeks.
We are committed to leveraging our intellectual property and the product development expertise of our highly experienced management team to enable
vascular targeted therapy to realize its true potential and to bring much needed new therapies for orphan oncology indications to cancer patients worldwide.
We have a portfolio of preclinical and clinical stage candidates focused on areas of significant unmet need that we believe can bring significant value to our shareholders.
Our common stock is traded on the OTCQB Market under the symbol “MATN”.
We are headquartered in Agoura Hills, California
https://www.oncotelic.com/pointr-data/
EdgePoint AI was established in order to advance the company’s revolutionary cluster-computer platform for AI that processes machine learning
models at a fraction of the power and budget of mainstream computing in pharmaceutical manufacturing.
The company’s technology solution “TrustPoint” provides an AI computing platform for pharmaceutical and healthcare verticals
including blockchain support for manufacturing where data integrity and security are of utmost importance.
EdgePoint is composed of a team of executives with pharmaceutical drug development, GMP manufacturing and deep AI knowledge.
The team includes Steven King who was the former CEO of Peregrine Pharmaceuticals, Inc. (NASDAQ) and its wholly-owned
contract biomanufacturing subsidiary Avid Bioservices, Inc., for over 15 years, during which time the company advanced its
lead compound through Phase 3 development, while growing revenues to over $55 million;
Seasoned executive, Saran Saund who has been founder, CEO and GM at several startups and public companies for which he returned
significant value to shareholders in his startups and chief technology officer; Burcak Beser who has been founder and
CTO of several successful private and public companies with over 144 patents during his career; and Lisa Stepp with broad experience in
executive leadership across geographies and in all aspects of drug development and program management.
The core technology platform for EdgePoint AI came from PointR -which was acquired by Mateon in Nov 2019. Examples of PointR capabilities are shown below.
http://oncotelic.com/wp-content/uploads/LosAngelesBusinessJournal2018-05-21.pdf
Health Care: Drug Developer Adds Digital Monitor
TWO YEAR CHART: NASDAQ
PER IHUB MGMT |
02-07-2021
DISCLAIMER: ONLY FOR MICK
https://investorshub.advfn.com/boards/profilea.aspx?user=1012
*The Board Monitor and herewithin , are not licensed brokers and assume NO responsibility for actions,
investments,decisions, or messages posted on this forum.
CONTENT ON THIS FORUM SHOULD NOT BE CONSIDERED ADVISORY NOR SOLICITATION
AUTHORS MAY HAVE BUYS OR SELLS WITH THE COMPANIES MENTIONED IN TRADING POSTERS SHOULD DUE DILIGENT BUYING OR SELLING.
ALL POSTING SHOULD BE CONSIDERED FOR INFORMATION ONLY. WE DO NOT RECOMMEND ANYONE BUY OR SELL ANY SECURITIES POSTED HEREWITHIN.
ANY trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.Any
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |